在欧洲心脏病学会（ESC）国会提供的新的亚分析提供了与长期使用Brilinta相关的心血管（CV）福利的其他证据
2017年8月24日
AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment withBrilinta（Ticagrelor）每天两次60mg，与安慰剂相比，服用低剂量阿司匹林的患者，但仍有动脉粥样硬化事件的高风险，这是急性冠状动脉综合征和CV死亡的主要原因。
Patients receivedBrilinta在患有心脏病发作（心肌梗塞，MI）的两年内，或在用二磷酸腺苷（ADP）抑制剂停止抗血小板治疗的一年内。最新结果强调了与长期治疗相关的潜在保护性简历益处，与标准的12个月后治疗期相比Brilinta60毫克，原定于西班牙巴塞罗那的ESC国会全面展出。
The favourable benefit-risk ratio for extended dual anti-platelet treatment withBrilinta60mg was suggested earlier in the PEGASUS trial that provided the data supporting the European Medicines Agency’s approval ofBrilintain the post-MI indication.
哥德堡大学心脏病学教授米凯尔·戴尔伯格（Mikael Dellborg）兼PEGASUS-TIMI 54试验指导委员会成员说：“临床医生和患者在MI高风险中的临床医生和患者的结论很明确：用来治疗Brilinta60mg, either as continuation therapy after the initial 12 month post-event period, or with as limited interruption as possible, is associated with a clear and favourable benefit-risk ratio for this population of patients. This new insight is potentially practice-changing, as while more than seven million people worldwide suffer a heart attack each year, we know that fewer than half receive adequate long-term treatment to reduce their risk of further CV events.”
The sub-analysis of PEGASUS-TIMI 54 data also showed a risk reduction of 20% in all causes of death, and 20% in the composite of CV death, MI or stroke. As expected, major bleeding rates were consistent with the known safety profile ofBrilinta。
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases (CVMD), Global Medicines Development, AstraZeneca, said: “The Phase III PEGASUS-TIMI 54 trial continues to provide valuable data and insights with the potential to benefit both healthcare professionals and their patients. The results reinforce the importance of our continued investment in the science, helping to understand better the unique CV and mortality benefits that our medicines, such asBrilinta, can provide for the millions of patients living with cardiovascular disease, the leading cause of death globally1。”
注释编辑
关于Brilinta(ticagrelor)
Brilinta是直接作用的P2Y12receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs).Brilintaworks by inhibiting platelet activation and has been shown to reduce the rate of atherothrombotic CV events, such as heart attack or CV death, in patients with acute coronary syndromes (ACS).
Brilinta, co-administered with aspirin, also known as acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with ACS, or for patients with a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
关于心血管，欧洲杯微信买球肾脏和代谢疾病（CVMD）中的阿斯利康（Astrazeneca）
心血管，肾脏和代谢性疾病共同构成了阿斯利康的主要疗法领域之一，以实现未来的增长。欧洲杯微信买球通过遵循科学，更清楚地了解心脏，肾脏和胰腺之间的潜在联系，阿斯利康正在投资一项药物组合，以保护器官和改善疾病进展，降低疾病的进展，降低风险并解决合并症。欧洲杯微信买球我们的野心是通过继续提供变革性的科学来修改或停止CVMD的自然过程，甚至是再生器官和恢复功能，从而改善全球数百万患者的治疗方法和CVMD健康。
关于阿斯利康欧洲杯微信买球
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.For more information, please visitwww.vivelima.com并在Twitter @Astrazeneca上关注我欧洲杯微信买球们。
参考
1.世界卫生组织。心血管疾病（CVD）情况说明书。2017年8月17日访问http://www.who.int/mediacentre/factsheets/fs317/en
CONTACTS
媒体查询 |
||
Esra Erkal-Paler |
UK/Global |
+44 203 749 5638 |
罗布·斯凯尔德（Rob Skelding） |
UK/Global |
+44 203 749 5821 |
卡伦·伯明翰 |
UK/Global |
+44 203 749 5634 |
Matt Kent |
UK/Global |
+44 203 749 5906 |
雅各布·隆德（Jacob Lund） |
Sweden |
+46 8 553 260 20 |
Michele Meixell |
我们 |
+1 302 885 2677 |
投资者查询 |
||
Thomas Kudsk Larsen |
+44 203 749 5712 |
|
克雷格·马克斯（Craig Marks） |
Finance, Fixed Income, M&A |
+44 7881 615 764 |
亨利·惠勒 |
Oncology |
+44 203 749 5797 |
米切尔·陈（Mitchell Chan） |
Oncology |
+1 240 477 3771 |
Christer Gruvris |
Diabetes; Autoimmunity, Neuroscience & Infection |
+44 203 749 5711 |
Nick Stone |
Respiratory,Brilinta |
+44 203 749 5716 |
我们免费电话 |
+1 866 381 7277 |